Clinical Trial Update: Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias [Phase 2]

View source ↗

Summary

Phase 2 open-label study assessing safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor GSK1120212 in relapsed or refractory leukemias; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• GSK1120212 (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-02-28